Oral tadalafil in pulmonary artery hypertension: A prospective study

Indian Heart Journal

Volumn 59, Issue 4, 2007, Pages 329-335

  Aggarwal, Pankaj ^a,b   Patial, Ramesh K ^a   Negi, Parkash C ^a   Marwaha, Rajeev ^a  

^a INDIRA GANDHI MEDICAL COLLEGE   (India)

^b NONE   (India)

Author keywords

Phosphodiesterase inhibitor; Pulmonary artery hypertension; Tadalafil

Indexed keywords

TADALAFIL;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; DRUG COST; DRUG DOSE INCREASE; DRUG EFFECT; DRUG TOLERANCE; FEMALE; HUMAN; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; PATHOGENESIS; PULMONARY HYPERTENSION; TREADMILL EXERCISE; TREATMENT OUTCOME; WELLBEING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CARBOLINES; EXERCISE TEST; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 37749007190     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. th ed. Philadelphia: W.B.Saunders, 2001:1908-1935.
2. Robbins SL. The lung. In: Pathologic basis of disease, Eds. Robbins SL, Cotran RS, Kumar V. Bangalore, Prism Books Pvt. (Ltd), 1994:681-682.
3. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111-117.
4. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361:1533-1544.
5. Rubin LJ. Therapy for pulmonary hypertension: the evolution from vasodilators to anti proliferative agents. Am J Respir Crit Care Med 2002; 166(10):1308-1309.
6. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296-302.
7. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106:1477-1482.
8. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40:780-788.
9. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
10. Newman JH. Treatment of primary pulmonary hypertension- the next generation. N Engl J Med 2002; 346:933-935.
11. Humbert M, Sanchez O, Fartoukh M, Jagot JL, Gall CL, Sitbon O, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999; 13: 1351-1356.
12. Galiè N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind placebo-controlled trial. J Am Coll Cardiol 2002; 39:1496-1502.
13. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41:2119-2125.
14. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329.
15. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Effect of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a one year follow-up study. Chest 2003; 124:247-254.
16. Hasuda T, Satoh T, Shimuchi A, Sakamaki F, Kyotani S, Matsumoto T, et al. Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension. Circulation 2000; 101:2066-2070.
17. Weimann J, Ullrich R, Hromi J, Fujino Y, Clark MWH, Bloch KD, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000; 92:1702-1712.
18. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawl. Anesthesiology 1990; 91:307-310.
19. Sastry BKS, Narasimhan C, Reddy NK, Anand B, Prakash GS, Raju PR, et al. A study of Clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J 2002; 54:410-414.
20. Mikhail GW, Prasad SK, Li W, Rogers P, Chester AH, Bayne S, et al. Clinical and hemodynamic effects of sildenafil in pulmonary hypertension: acute and mid term effects. European Heart J 2004; 25:431-436.
21. Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J 2002; 54:404-449.
22. Beavo JA. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995; 75:725-748.
23. Singh B, Gupta R, Punj V,Ghose T, Sapra R, Grover DN, et al. Sildenafil in the management of primary pulmonary hypertension. Indian Heart J 2002; 54:297-300.
24. Prasad S, Wilkinson J, Gatzouli MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000; 343:1342.
25. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreekel A, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167:1139-1141.
26. Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolhe T, Behr J. Hemodynamic response to sildenafil, nitric oxide and iloprost in primary pulmonary hypertension. Chest 2004; 125:580-586.
27. Galiè N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002; 20:1037-1049.
28. Castelain V, Chemla D, Humbert M, Sitbon O, Simonneau G, Lecarpentier Y, et al. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med 2002; 165:338-340.
29. Grimminger F, Spriestersbach R, Weissmann N, Walmrath D, Seeger W. Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. J Appl Physiol 1995; 78:1509-1515.
30. Weirsmann N, Winterhalder S, Nollan M, Voswinckel R, Ganz K, Ghofrani HA, et al. NO reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. Am J Physiol Lung Cell Mol Physiol 2001; 280:L638-645.
31. Ide H, Nakano H, Ogasa T, Osanai S, Kikuchi K, Iwamoto J. Regulation of pulmonary circulation by alveolar oxygen tension via airway nitric oxide. J Appl Physiol 1999; 87:1629-1636.
32. Ghofrani HA, Wiedmann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002; 360:895-900.